...
机译:药物洗脱支架后12个或30个月的双抗血小板治疗
Harvard Clinical Research InstituteBoston United States Division of Cardiovascular Medicine;
Christ Hospital Heart and Vascular Center Lindner Center for Research and EducationCincinnati;
Harvard Clinical Research InstituteBoston United States Harvard Medical SchoolBoston United;
Harvard Clinical Research InstituteBoston United States;
Harvard Clinical Research InstituteBoston United States Harvard Medical SchoolBoston United;
Département Hospitalo-Universitaire Fibrosis Inflammation Remodeling H?pital Bichat Assistance;
Harvard Medical SchoolBoston United States Harvard School of Public HealthBoston United States;
Division of Cardiovascular Medicine Department of Medicine Brigham and Women's Hospital 75;
Division of Cardiovascular Medicine Department of Medicine Brigham and Women's Hospital 75;
Saint Luke's Mid America Heart Institute University of Missouri-Kansas City School of;
Jr. Mayo ClinicRochester MN United States;
Duke University Medical CenterDurham NC United States;
St. Vincent Heart CenterIndianapolis United States;
University of VermontBurlington United States;
University Hospitals Case Medical CenterCleveland United States;
Piedmont Heart InstituteAtlanta United States;
Lenox Hill HospitalNew York United States;
Stanford UniversityStanford CA United States;
Great Lakes Heart and Vascular InstituteSt. Joseph MI United States;
Eastern Maine Medical CenterBangor United Kingdom;
Sanger Heart and Vascular Institute Carolinas HealthCare SystemCharlotte NC United States;
Harvard Clinical Research InstituteBoston United States Boston University School of Public;
机译:糖尿病患者第二代药物洗脱支架植入后双重抗血小板治疗的最佳持续时间:安全性(第二代药物洗脱支架植入,然后进行六对十二个月双重抗血小板治疗)-糖尿病亚研究
机译:药物洗脱支架后12个或30个月的双抗血小板治疗
机译:药物洗脱支架后12个或30个月的双抗血小板治疗
机译:双药物洗脱支架的ReoPro和ALA药物的特性和控制释放
机译:使用有限元分析(FEA)的药物洗脱支架(DES)医疗设备的连续体变形模型
机译:药物洗脱支架后的十二个月或三十个月的双重抗血小板治疗
机译:药物洗脱支架后的十二个月或30个月双重抗血小板治疗。